Study reveals immune-modulatory mechanism of lurbinectedin in small-cell lung cancer
Researchers at the Icahn School of Medicine at Mount Sinai have identified the mechanism of action of a treatment for ...
Cure Today5d
FDA Grants Breakthrough Therapy Designation to Trodelvy for Small Cell Lung Cancer
The FDA has granted breakthrough therapy designation Trodelvy for adults with extensive-stage small cell lung cancer who ...
Zacks.com on MSN11d
GILD's Trodelvy Gets Second Breakthrough Therapy Tag for Lung Cancer
Gilead announces that the FDA grants a second Breakthrough Therapy designation to Trodelvy for the extensive-stage small cell ...
WebMD20d
FDA Approves Drug for Aggressive Small-Cell Lung Cancer
The FDA has approved the drug durvalumab for adults with limited-stage small-cell lung cancer (LS-SCLC) whose disease hasn’t gotten worse after getting platinum-based chemo and radiation at ...
FDA Grants Breakthrough Therapy Status To Gilead's Trodelvy For Treatment Of Small Cell Lung Cancer
(RTTNews) - Gilead Sciences, Inc. (GILD) Tuesday said that the U.S. Food and Drug Administration or FDA has granted Breakthrough Therapy Designation to Trodelvy for the treatment of adults with ...
Daily10d
Gilead Sciences earns USFDA Breakthrough Therapy Designation for lung cancer treatment Trodelvy
Gilead Sciences, Inc. has announced that Trodelvy (sacituzumab govitecan-hziy) has received Breakthrough Therapy Designation ...
Pharm Exec24d
FDA Approves AstraZeneca’s Imfinzi for Limited-Stage Small Cell Lung Cancer
The FDA has approved AstraZeneca’s Imfinzi (durvalumab) to treat adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed after platinum-based chemotherapy and ...
Targeted Oncology12d
FDA Grants Breakthrough Status to Sacituzumab Govitecan in ES-SCLC
The FDA granted breakthrough therapy designation to sacituzumab govitecan for patients with ES-SCLC progressing on platinum ...
GlobalData on MSN12d
GSK’s lung cancer therapy gains EMA PRIME designation
GlaxoSmithKline (GSK)’s B7-H3-targeted antibody-drug conjugate (ADC), GSK’227 has gained priority medicines (PRIME) ...
Pharmabiz23d
AstraZeneca’s Imfinzi receives US FDA approval to treat patients with limited-stage small cell lung cancer
AstraZeneca’s Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following ...
FiercePharma24d
AstraZeneca scores FDA nod for Imfinzi as first immunotherapy for limited-stage small cell lung cancer
as the FDA has blessed the PD-L1 inhibitor for limited-stage small cell lung cancer (LS-SCLC) patients who have not had disease progression after concurrent chemotherapy and radiation treatments.
The Pharma Letter11d
FDA Breakthrough status for Trodelvy in ES-SCLC
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Trodelvy (sacituzumab ...